August 12, 2025 • Novartis.com Novartis announces both ianalumab Phase III clinical trials met primary endpoint in patients with Sjögren’s disease - Novartis Ad hoc announcement pursuant to Art. 53 LR NEPTUNUS-1 and NEPTUNUS-2 are the first ever global phase III trials to demonstrate statistically significant reduction in disease activity for Sjö… Share this article Twitter Facebook LinkedIn WhatsApp Telegram Email Reddit Back to Blog
